Mlp Saglik Hizmetleri As Class B · BIST:MPARK
Mlp Saglik Hizmetleri As Class B — MLP Care — H1 2022 Earnings Presentation
24 slides from Mlp Saglik Hizmetleri As Class B's earnings presentation, Aug 12, 2022
Slide 1: MLPCARE H1 2022 Presentation
MLPCARE H1 2022 PRESENTATION A U G U S T 1 2 th, 2 0 2 2
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain certain forward-looking statements concerning MLP Care’s future performance and should be considered as good faith estimates made by the Company. These forward-looking statements reflect management expectations and are based upon currently ava
Slide 3: Muharrem Usta, Chairman & CEO
MUHARREM USTA CHAIRMAN & CEO
Slide 4: MLP Care: The #1 Private Hospital Group in Turkey
Türkiye’nin MLP Care: The 1 Numaralı #1 Private Hospital Özel Group in Turkey Hastane Grubu Two brands and one concept targeting three different price points with The largest hospital group in 27 Hospitals in consistently outstanding medical service Total Turkey quality Established in 1993, listed o
Slide 5: At a Glance: MLP Care Q2 2022 Financial Highlights
At a Glance: MLP Care Q2 2022 Financial Highlights Revenue growth exceeding inflation Revenue EBITDA EBITDA improved mainly due to TL 2,230 m TL 539 m 68% Growth 77% Growth strong operational performance H1 2022: H1 2022: effective cost saving measures 74% Growth 74% Growth Reduced leverag
Slide 6: # of People Top-up Insurance Users Reached 2.9 m
# of People Top-up Insurance Users Reached 2.9 m # of People with Insurance in Turkey (in thousand) 2,571 2,899 5,469 2,399 2,022 4,421 Growth (H1 2022 – H1 2021) 7.1% 43.3% 23.7% PMI Top-up PMI+Top-up # of People with Top-up Insurance in Turkey (in thousand) 6.2022; 2,899 6.2021; 2,022 Average LTM
Slide 7: FMT Revenue triples in TL terms
FMT Revenue tripples in TL terms Medical Tourism Revenue (USD m) TOP 10 FMT Revenue % by Department in H1 2022 51.8% 49 47.5% 12% 11% 32 11% 10% 6% 5% 3% 3% 3% 3% 25 Hematology Hematology Orthopedics Oncology Oncology Cardiology Ear-Nose-Throat General Surgery Brain and Neuro Gynecology and Radiatio
Slide 8: Liv Hospital Brand Expands in Baku
Liv Hospital Brand Expands in Baku Map of Azerbaijan Liv Bona Dea Hospital Location: Baku / Azerbaijan Opening Date: July 2021 Key Statistics 37.5k sqm 156 Bed Capacity 28 Intensive Care Unit 12 Operating Rooms 8
Slide 9: Slide 9
Slide 10: Revenue grows above inflation
Revenue grows above inflation Revenue (TLm) 87.6% 73.7% 4,417 88.4% 67.5% 2,542 2,230 1,331 Q2 2021 Q2 2022 H1 2021 H1 2022 Denotes growth of Revenue vs. the same period of the last year 10 Denotes growth of Revenue vs. the same period of the last year excluding Sentez
Slide 11: All payer types continue to grow
All payer types continue to grow H1 2022 150% Revenue from SSI was up by 30% in Q2 2022 4% (SSI Insurance allows for a wide addressable market, 186% 36% which is c.98% of the total population) 20% 16% Self pay was up by 50% in Q2 2022 Revenue from PMI, Top-up & Contracted Institutions was up b
Slide 12: All revenue segments continue to grow
All revenue segments continue to grow Domestic Patient Medical Tourism Ancillary Business Revenue Revenue 58.7% 186.2% 150.2% 3,532 177.5% 160 52.2% 724 132.7% 1,762 399 69 Q2 2022 H1 2022 Q2 2022 H1 2022 Q2 2022 H1 2022 Domestic Revenue q-o-q Growth Accelerated Growth of Foreign Increase in Managed
Slide 13: Continued Improvement in Average Prices
Continued Improvement in Average Prices Outpatient Revenues (TLm) Inpatient Revenues (TLm) 68.0% 52.5% 50.7% 19.2% 17.3% 33.3% 255 455 441 156 1,509 2,024 898 1,327 H1 2021 Volume & Mix Price H1 2022 H1 2021 Volume & Mix Price H1 2022 Average Revenue Per Visit (ARPV) Average Revenue Per Protocol (AR
Slide 14: EBITDA is up by 74%
EBITDA is up by 74% EBITDA (TLm)1 80.3% 74.4% 90.9% 1,040 76.8% 596 539 305 1 1 Q2 2021 Q2 2022 H1 2021 H1 2022 1 EBITDA and EBITDA margin calculated by deducting general administrative expenses from gross profit and adding depreciation and amortization expenses Denotes growth of EBITDA vs. the same
Slide 15: Prudent Cost Management
Prudent Cost Management Cost of Service and G&A Expenses as a % of Revenues Cost Saving Measures enables us to reach the favourable EBITDA Margin EBITDA Margin 23.4% 23.5% Material costs as a % of revenue decreased in H1 2022 due to the lagging effect of increased costs on the back 0.8% 1.2% of ef
Slide 16: Bottom line improves on the back of strong operations
Bottom line improves on the back of strong operations Net Profit (TLm) Net Profit (TLm) Allocated to Equity Holders of the Parent 246.4% 208.6% 291.6% 327.7% 604 577 251.6% 398.2% 404 407 174 147 95 82 Q2 2021 Q2 2022 H1 2021 H1 2022 Q2 2021 Q2 2022 H1 2021 H1 2022 Denotes growth of Net Profit and N
Slide 17: Leverage Ratios continue to decline
Leverage Ratios continue to decline 2500.0 Net Debt (TLm) 4.00 3.500 2000.0 2,116 2,069 3.00 1500.0 1,521 2.500 2.2x 1,344 Reduction 345mTL 1,176 2.00 1000.0 1.5x 1.500 Reduction 689mTL 500.0 487 1.00 0.7x - .500 2020 2021 H1 2022 Net Debt (exc. IFRS 16) Net Debt (inc. IFRS 16) Net Debt/EBITDA FX
Slide 18: Strong Cash Generation
Strong Cash Generation Maintenance Capex (TLm) Total Capex (TLm) OCF/ EBITDA FCF/ EBITDA 6.7% 80.9% 50.9% 58.9% 37.0% 5.1% 2.8% 2.1% 125 224 384 482 612 304 169 53 H1 2021 H1 2022 H1 2021 H1 2022 H1 2021 H1 2022 H1 2021 H1 2022 % of Revenue % of Revenue % of EBITDA % of EBITDA 18
Slide 19: Q&A
Q&A
Slide 20: Closing Remarks
Closing Remarks MUHARREM USTA CHAIRMAN & CEO
Slide 21: Thank You!
Thank You! MLP Care Investor Relations Deniz Can Yücel +90 212 227 5555 (Ext: 1148) deniz.yucel@mlpcare.com http://investor.mlpcare.com/en/
Slide 22: Historical Balance Sheet
Historical Balance Sheet Reviewed Reviewed Audited TLm June 30, 2022 June 30, 2021 December 31, 2021 Cash and cash equivalents 1,158 580 680 Financial investments 186 - - Trade receivables 1,083 1,279 1,318 Inventory 436 118 285 Short term other assets 539 454 458 Current assets 3,403 2,431 2,741 Ta
Slide 23: Historical P&L Statements
Historical P&L Statements TLm H1 2022 H1 2021 Change (%) Q2 2022 Q2 2021 Change (%) Revenues 4,417 2,542 73.7% 2,230 1,331 67.5% Cost of service (-) (3,189) (1,907) 67.2% (1,593) (999) 59.5% Gross profit 1,228 635 93.2% 637 332 91.7% General administration expenses (-) (399) (194) 105.9% (201) (109)
Slide 24: EBITDA Reconciliation
EBITDA Reconciliation TLm H1 2022 H1 2021 Q2 2022 Q2 2021 Revenue 4,417 2,542 2,230 1,331 Cost of service 3,189 1,907 1,593 999 Gross profit 1,228 635 637 332 General administrative expenses (-) (399) (194) (201) (109) Depreciation and amortization expenses (Cost of service) 196 144 95 76 Depreciati